Caribou Hit By Familiar Allo CAR-T Durability Problems
Hope For Higher Dose
Like some of its allo CAR-T rivals, CB-010’s early promise has fallen away, but Caribou still hopes a higher dose can bring with it real durability of response.
You may also be interested in...
Allogene Frustrated By FDA’s Delayed CAR-T Trial Review
Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”
Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche
The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.
PD-1 Knockout Could Be Caribou’s Key To Allo CAR-T Success
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.